Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12992657 | 0.94 | MEN1 (0.51) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL3423368 | 0.94 | MEN1 (0.62) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL3423261 | 0.93 | MEN1 (0.55) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL3423033 | 0.92 | MEN1 (0.50) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL4169676 | 0.91 | MEN1 (0.54) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL3351219 | 0.90 | MEN1 (0.54) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL12992658 | 0.90 | MEN1 (0.53) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL3418070 | 0.90 | MEN1 (0.61) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL3423309 | 0.90 | MEN1 (0.55) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL3346683 | 0.90 | MEN1 (0.50) | MEN1KMT2AALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714135-B2 | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer | 4SC AG (DE) | 2010-05-11 | — | — | US | claimed |
| US-20090227577-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2009-09-10 | — | — | US | claimed |
| US-20080096914-A1 | Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer | ALTANA PHARMA AG (DE) | 2008-04-24 | — | — | US | claimed |
| EP-1851229-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | Nycomed GmbH (DE) | 2007-11-07 | — | — | EP | claimed |
| WO-2006084869-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | NYCOMED GMBH (DE) | 2006-08-17 | — | — | WO | claimed |
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2010-12-23 | — | — | US | disclosed |
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2010-12-23 | — | — | US | disclosed |
| US-7714135-B2 | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714135-B2 | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090227577-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2009-09-10 | — | — | US | disclosed |
| US-20090227577-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2009-09-10 | — | — | US | disclosed |
| US-20080096914-A1 | Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer | ALTANA PHARMA AG (DE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096914-A1 | Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer | ALTANA PHARMA AG (DE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096914-A1 | Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer | ALTANA PHARMA AG (DE) | 2008-04-24 | — | — | US | disclosed |
| EP-1851229-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | Nycomed GmbH (DE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006084869-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | NYCOMED GMBH (DE) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096914-A1 | Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer | MKI67, CCNT1, RB1 | MEN1 2714/4885KMT2A 1982/4885ALDH1A1 546/4885 |
| US-20090227577-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | CCNO, CCNY, CCNT1 | MEN1 3314/4885KMT2A 779/4885ALDH1A1 1514/4885 |
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | CCNT1, MALT1, CCNA1 | MEN1 2581/4885KMT2A 660/4885ALDH1A1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.